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ABSTRACT
Introduction: A1chieve
 (ClinicalTrials.gov
identifier NCT00869908) was a 24-week
observational study evaluating certain insulin
analogs and not insulin analogs in general in
66,726 people with type 2 diabetes (T2D) in
routine clinical care in 28 non-Western
countries. This study demonstrated that
insulin analogs improved self-management
and metabolic control in patients with T2D.
We investigated the effectiveness and clinical
characteristics of patients with T2D showing
better response to basal insulin (BI) (detemir),
using data from the A1chieve study performed
in Korea.
Methods: Subjects were classified into two
groups according to the achievement of target
glycated hemoglobin (A1c) level of \7.5%.
Multivariate logistic regression analysis was
performed to determine the variables
independently associated with the
achievement of target A1c level.
Results: Baseline A1c, postprandial glucose
(PPG), difference between PPG and fasting
plasma glucose, and duration of diabetes were
independently associated with better response
to BI after adjusting for other risk factors.
Compared to patients with BI use at evening,
those who took BI in the morning
demonstrated a larger reduction in A1c level.
Conclusion: Once-daily BI therapy appears to
be effective in Korean subjects with type 2
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INTRODUCTION
The A1chieve
 study (ClinicalTrials.gov
identifier NCT00869908) enrolled 66,726
patients with type 2 diabetes (T2D) and was a
24-week, prospective, multinational (28
countries), open-labeled, observational study
that evaluated the clinical safety and
effectiveness of insulin analogs in routine
clinical care in non-Western countries [1]. This
study showed that the treatment with insulin
analogs provides a valuable option for broad
improvements in self-management and
metabolic control, regardless of the types of
insulin used [2]. In the A1chieve study
conducted in Korea, therapy with modern
insulin analogs significantly reduced the levels
of glycated hemoglobin (A1c), fasting plasma
glucose (FPG), and postprandial plasma glucose
(PPG) (-1.6 ± 2.2%, -2.5 ± 4.7 mmol/L, and
-4.0 ± 6.4 mmol/L, respectively) at 24 weeks.
In addition, no major hypoglycemic episodes
were observed, and the rate of minor
hypoglycemic episodes was marginally
decreased [3]. However, many questions
remain regarding the optimal approach for
initiating insulin analogs, including type(s) of
insulin (basal, rapid-acting, biphasic, or a
combination of basal and rapid-acting),
continuation or discontinuation of oral
anti-diabetic drugs with insulin analogs in
insulin-naı¨ve subjects, as well as insulin
regimen (basal, rapid-acting, biphasic, or a
combination of basal and rapid-acting).
Although previous studies have evaluated the
characteristics of Korean T2D patients showing
better response to biphasic insulin analog (BIA)
therapy [4–6], it is still uncertain regarding the
characteristics of patients who show better
response to basal insulin (BI) analog therapy.
In addition, the latest sub-analysis from the
A1chieve study conducted in Korea included
3074 patients who were analyzed in three
groups regarding A1c \7.5%/7.5–9%/[9%. No
significant A1c reduction was observed with any
insulin regimens in Korean patients with
relatively well-controlled T2D (A1c \7.5%), a
basal–bolus regimen may be adequate for
Korean patients with poorly controlled T2D
(A1c C9.0%) [7]. Therefore, using data from the
A1chieve study in Korea, we investigated the
effectiveness of the BI analog, insulin detemir
(Levemir) in Korean patients with T2D. In
particular, we provide the characteristics of
patients showing better response to insulin
detemir in Korean patients with type 2 diabetes.
METHODS
Patients and Study Design
A total of 104 sites from South Korea were
involved in this study. The study population
and design were described in a previous report
[3]. Briefly, the inclusion criteria were Korean
patients with T2D who planned to use or who
had started the study products (biphasic insulin
aspart 30 [BIA30], insulin detemir, or insulin
aspart) within 4 weeks of inclusion in this
study. Patients were excluded for the following
reasons: hypersensitivity to the study products,
pregnancy, breastfeeding, or intention of
becoming pregnant within the next 6 months.
We selected subjects who were treated with
insulin detemir once daily. The data were
collected at baseline, at an interim visit
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approximately 12 weeks after the baseline visit,
and at a final visit approximately 24 weeks after
the baseline visit. The primary endpoint was
serious adverse drug reactions including major
hypoglycemic events. The secondary study
endpoints were effectiveness (changes in FPG,
PPG after breakfast, A1c and lipid profile) and
safety (changes in number of hypoglycemic
events and nocturnal hypoglycemic events,
number of adverse drug reactions). According
to usual practices, the physicians were free to
determine all decisions on subsequent
treatment, as well as the discontinuation of
insulin. The study was performed in accordance
with the Declaration of Helsinki 1964, as revised
in 2013, and the guidelines for Good
Pharmacoepidemiology Practices. The protocol
was reviewed and approved by independent
institutional review boards at 104 study sites
(Representative site: Yonsei University College
of Medicine Institutional Review Board number:
4-2009-0359), and all participants provided
written informed consent before any
trial-related activity.
Analysis Design
The A1chieve study in Korea reported a decrease
in A1c from 9.4 ± 1.9% at baseline to
8.0 ± 1.4% at 24 weeks in insulin
detemir-treated subjects [3] and no significant
A1c reduction with any insulin regimens (BI,
bolus regimen and basal–bolus regimen and
biphasic regimen) in Korean patients with
relatively sub-optimally controlled (A1c
\7.5%) T2D [7]. Another previous
observational study, similar result showed that
reduction in A1c was 7.6% of final A1c from
8.9% of baseline A1c. Higher baseline A1c leads
to more decline of A1c. However, their final A1c
levels were not less than 7%, but around 7.5%
[8]. Based on these findings, we hypothesized
that achieving A1c levels less than 7.5% might
be optimal in real clinical practice and classified
the study subjects into two groups according to
the response to insulin detemir. Group I had an
A1c\7.5%, and group II had an A1c C7.5%. We
investigated the variables predictive of
achieving the glycemic control target with BI
analogs in T2D patients. We also compared the
effectiveness and safety of insulin detemir
according to the time of injection. We
excluded subjects who did not have records
about insulin administration time.
Statistical Procedures
Data were expressed as mean ± standard
deviation or as proportion. The comparison of
effectiveness of the endpoints based on A1c
level was performed using analysis of variance
(ANOVA) with repeated measures. The mean
improvement from baseline A1c and
corresponding 95% confidence interval (CI)
was calculated and compared between
treatment groups using the t test. The
association between the effect of the treatment
group and the degree of hyperglycemia was
represented by n (%) at different levels of A1c at
the end of the trial. To determine the variables
predictive of achieving the glycemic control
target with BI analogs in T2D patients, multiple
logistic regression analysis was performed with
clinically relevant variables and established
parameters that significantly differed between
responders and non-responders in our study.
Multivariate regression analysis was used to
estimate multiple correlations between
achievement of an A1c less than 7.5% and
clinical and laboratory risk factors. A variance
inflation factor[10 suggests an erroneous
model; all such items were omitted from the
models. All data were analyzed by Novo Nordisk
using SAS (Version 9.1.3, SAS Institute Inc.
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North Carolina, USA). p values \0.05 were
considered statistically significant.
RESULTS
Study Population
The study population and analysis design were
described in previous reports [3, 7]. Briefly, of
the 4058 patients who were administered study
insulin at least once in the full analysis set
(FAS), 3074 had A1c level measured at baseline
and at the final visit; and 2952 (72.7% of the
FAS) who received one of the four insulin
analog regimens were eligible for analysis. In
clinical practice, more Korean physicians chose
insulin detemir over BIA30 as a BI (2083 vs.
1434, respectively). Of the 2083 BI-enrolled
subjects, 1542 completed the 6-month study.
As per the analysis data sets, 14 subjects were
not part of the efficacy analysis, and thus there
was a difference in the number of subjects
between the completed and efficacy analysis
sets. Of the 1528 subjects on insulin detemir
who were eligible for efficacy analysis, 816 had
data sufficient for sub-analysis of the efficacy
and safety in T2D according to injection time
and responsiveness (Fig. 1).
There were no restrictions on entry into the
study, with relationship to baseline A1c levels.
Participants were free to withdraw at will at any
time. Therefore, it could not be identified why
individuals were registered and what made
physicians prescribe insulin regimen. Possible
causes include impaired cardiac, liver, and/or
renal function; oral ingestion discomfort such
as dysphagia; need for a stable glycemic control;
active demand for new treatment; requirements
due to adverse effects before treatment; and
willing to participate in research and insurance
policies—reimbursement guideline, etc.
In this study, the insulin therapies were
prescribed by a physician in the course of
clinical practice, were commercially available
and were funded according to local practice in
routine care.
Fig. 1 Flowchart illustrating the number of patients included in the A1chieve
 sub-study in Korea. HbA1c glycated
hemoglobin
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Baseline Clinical and Laboratory
Characteristics at Study Entry According
to Target A1c
Patients were allocated to group I (A1c\7.5%,
n = 100; 55 men and 45 women) and group II
(A1c C7.5%, n = 716; 378 men and 338 women)
based on responsiveness to insulin detemir. The
male-to-female ratio in the two groups was
similar (p = 0.6787). Table 1 shows the baseline
characteristics of the study patients according
to the achievement of a target A1c of 7.5%. For
groups I and II, the mean age, the duration of
diabetes and average body mass index (BMI)
were similar. Compared to patients who were
non-responsive to once-daily insulin detemir
(group II, A1c C7.5%), responsive subjects had
significantly lower baseline glucose parameter
markers such as FPG, PPG, and serum A1c level.
The patients in group II showed a tendency for
greater difference in glucose level (D
glucose = PPG - FPG) than those in group I.
Total cholesterol and triglycerides were
significantly higher in group II than in group I
(p = 0.0024 and 0.0386, respectively). In
addition, non-HDL cholesterol (mmol/L) was
also statistically different between the two
groups (3.1 in group I vs. 3.6 in group II,
p = 0.0132). The patients in group II were more
significantly dependent on sulfonylurea
(SU)-treatment (SU alone or SU plus
metformin). Systolic blood pressure and other
plasma lipids were not significantly different
between the two groups.
The baseline characteristics of age, diabetes
duration, body weight, BMI, systolic BP, FPG,
PPG, PPG minus FPG, A1C, total cholesterol,
triglyceride, HDL cholesterol, and LDL
cholesterol were analyzed using the t test at a
5% level of significance. Other parameters such
as proportion of male patients (%) and
concomitant OAD use (baseline/at last
follow-up) were analyzed using Chi-square
test. The p values were presented for testing
statistical significance. Agent other than the
above OADs or their combinations included
glinide, a-glucosidase inhibitor, DPP4-inhibitor.
Efficacy and Safety of 6 Months of Insulin
Detemir Treatment According to Injection
Time
To compare whether the effectiveness and
safety of BI depends on injection time, the
subjects were classified into two groups
depending on whether BI was injected in the
morning or in the evening. Of the 816 subjects,
91.9% (n = 750) were injected with insulin
detemir in the morning, whereas 66 patients
had evening injections (Table 2). The
reductions in A1c were significantly larger in
subjects who were injected with insulin detemir
in the morning than those who were injected
with insulin detemir in the evening. No major
hypoglycemic episodes were reported, but 267
patients in the original A1chieve study in Korea
reported 559 minor episodes, including 451
diurnal and 108 nocturnal episodes [3]. In this
sub-analysis of BI, subjects who were injected in
the morning received a larger amount of insulin
dose than those who were injected in the
evening (0.38 vs. 0.34 U/kg, respectively,
p = 0.049) and frequently experienced minor
(5.35% vs. 5.20%, respectively, p\0.001) and
nocturnal hypoglycemic episodes (1% vs. 0%,
respectively, p = 0.004). Body weight gain was
not different between the two groups.
For multiple logistic regression analysis,
achievement of an A1c less than 7.5% was
used as a dependent variable. Age, gender, BMI,
duration of diabetes, total cholesterol, and
glycemic indices including PPG and D glucose
were independent variables based on the results
of Table 1 and the conventional risk variables in
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Table 2. In this analysis, we used two statistical
models with different independent variables.
We adopted PPG and D glucose as the glycemic
index in models 1 and 2, respectively. Age was
independently correlated with more responsive
glycemic control in both models (age, p = 0.01
and 0.02 in models 1 and 2, respectively). The
A1c, PPG, and D glucose were also
Table 1 Baseline characteristic of the subjects treated with insulin detemir according to achievement of an A1c 7.5%
Groups according to A1c at ﬁnal follow-up p value
<7.5% (N5 100) ‡7.5% (N5 716)
Age (years) 58.2 ± 12.7 57.6 ± 12.4 0.6747
Male (N, %) 55 (55.0%) 378 (52.8%) 0.6787
Diabetes duration (years) 10.4 ± 7.6 10.0 ± 7.2 0.5888
Body weight (kg) 64.4 ± 10.9 63.8 ± 10.9 0.57
BMI (kg/m2) 24.5 ± 3.5 24.3 ± 3.3 0.565
Systolic BP (mmHg) 127.0 ± 16.4 127.1 ± 15.5 0.9613
Creatinine (mmol/L) 88.5 ± 31.7 85.3 ± 27.8 0.4152
Plasma glucose level (mmol/L)
FPG 7.7 ± 2.7 11.4 ± 4.3 \0.0001
PPG 11.6 ± 3.7 16.3 ± 5.6 \0.0001
PPG minus FPG 3.4 ± 2.8 5.0 ± 4.8 0.0515
Baseline A1c (%) 6.9 ± 0.5 9.8 ± 1.8 \0.0001
Lipid (mmol/L)
T. Chol. 4.2 ± 1.1 4.8 ± 1.3 0.0024
TG 1.5 ± 0.8 1.9 ± 1.3 0.0386
HDL 1.1 ± 0.4 1.2 ± 0.3 0.1011
LDL 2.6 ± 1.3 2.8 ± 1.0 0.2889
Concomitant OAD [baseline (%)/at ﬁnal follow-up (%)]
S alone (10.0/7.0) (6.70/6.84) \0.000/\0.000
M alone (11.0/17.0) (9.36/26.26) \0.000/\0.000
T alone (1.0/1.0) (0.28/0.84) 0.5637/0.0588
S ?M (22.0/20.0) (28.07/27.37) \0.000/\0.000
S ? T (0.0/0.0) (0.84/0.0) ND
M ? T (0.0/0.0) (2.23/1.12) ND
Agent other than the above OADs
or their combinations
(37.0/37.0) (36.31/27.51) \0.000/\0.000
A1c glycated hemoglobin, BMI body mass index, BP blood pressure, FPG fasting plasma glucose, HDL HDL cholesterol,
LDL LDL cholesterol, M metformin, ND not determined, OAD oral anti-diabetic drugs, PPG postprandial glucose,
S sulfonylurea, T. Chol total cholesterol, TG triglyceride, T thiazolidinedione
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independently correlated with less responsive
glycemic control after multivariate adjustment
for other risk factors in models 1 and 2 (A1c,
p\0.01 in both models; PPG, p\0.01, model 1;
D glucose, p\0.01, model 2). The duration of
diabetes was significantly correlated with less
responsive glycemic control in model 2
(p = 0.01 in model 2) but only showed a trend
in model 1 (p = 0.03 but the 95% CI included
1.0) (Table 3).
The comparison of efficacy and safety
parameters of changes in FPG, PPG, PPG-FPG,
A1C, and body weight from baseline to after
6 months of treatment with insulin detemir
according to injection time (Breakfast,
n = 1102; Dinner, n = 97) were analyzed using
the t test at a 5% level of significance (Table 2).
The proportion of hypoglycemia events was
analyzed using Chi-square test. The p values are
presented for testing statistical significance. The
p values were presented as ‘NS’ for p[0.05.
The factors associated with more responsive
glycemic control on basal insulin such as PPG
and D glucose were analyzed using multiple
logistic regression analysis based on an A1c
threshold of 7.5% as the dependent variable and
age, gender, BMI, duration of diabetes, total
cholesterol, and glycemic indices including PPG
and D glucose as independent variables
(Table 3). The odds ratio and corresponding
95% CI as well as the p values are presented for
testing statistical significance.
DISCUSSION
Despite the greater glycemic effectiveness of
twice-daily injection of BIA or basal–bolus
regimens compared to once-a-day BI [4, 9, 10],
patients are often reluctant to start with
twice-daily injections of BIA or basal–bolus
regimens, especially those who are insulin
Table 2 Efﬁcacy and safety comparison after 6 months of treatment with insulin detemir according to injection time
Breakfast (n5 750) Dinner (n5 66) p value
D Body weight (kg) 0.39 ± 2.8 0.10 ± 2.1 NS
Plasma Glucose Level (mmol/L)
D FPG -3.2 ± 4.1 -2.9 ± 4.2 NS
D PPG -4.2 ± 6.3 -3.8 ± 5.6 NS
D PPG minus FPG -0.6 ± 5.6 0.3 ± 4.6 NS
D A1c (%) -1.6 ± 2.0 -0.9 ± 1.8 0.01
Insulin dose (U/kg) 0.38 ± 0.17 0.34 ± 0.15 0.049
In A1c B6.5% 0.30 ± 0.15 0.22 ± 0.12 NS
In A1c\7.0% 0.34 ± 0.15 0.32 ± 0.12 NS
In A1c\7.5% 0.35 ± 0.16 0.32 ± 0.11 NS
Hypoglycemia (N, %)
Minor 59 (5.35%) 3 (5.20%) \0.0001
Major 0 (0.00%) 0 (0.00%) ND
Nocturnal 11 (1.00%) 1 (0.00%) 0.004
A1c glycated hemoglobin, FPG fasting plasma glucose, ND not detected NS not signiﬁcant, PPG postprandial glucose
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naı¨ve [11, 12]. In addition to the obstacles in
initiating basal insulin therapy, many questions
remain regarding the optimal target A1c and
the approach for initiating insulin analog
therapy. Basal insulin therapy works to control
fasting glycemia, and it is expected that other
drugs will suffice apropos postprandial
glycemia. In many patients, however, basal
insulin is unable to achieve adequate glycemic
control. This might be associated with basal
insulin inadequacy. All basal insulins are not
alike. Each basal insulin and basal analogue has
a unique structure and characteristics including
duration of action, glycemic variability and risk
of hypoglycemia. These differences may bring
that one basal insulin substitute for another, in
case adequate control is not achieved with a
particular preparation [13]. Studies
investigating the predictive characteristics of
patients who respond well to BI analog
(detemir) therapy have been especially lacking
in Korean patients with T2D.
This sub-analysis of A1chieve study in Korea
revealed that once-daily basal insulin given in
the morning is preferable in Korean patients
with T2D. There was a better response in
patients who had older age, shorter duration
of diabetes, well-controlled glycemic status (i.e.,
patients with lower A1c, lower PPG and lower D
glucose) and were not taking sulfonylurea.
A recent paper, confirming the predictive
factors of insulin analog user in A1chieve study,
reported that a higher baseline A1c resulted in a
comparatively lower final A1c. This study was
the result of analysis of patients from 28 various
countries [14]. Whereas in our analysis of
Korean patients, the patients with lower A1c
showed better response, which could be
attributed to racial differences in insulin
response. The biggest difference is considered
from the origin of study analysis methods. In
this study, the responders were defined as
having final A1c lower than 7.5%, but on the
other hand, the previous study had adopted
delta A1c as a dependent value.
In the previous study, with every increase of
1.0% in baseline A1c, the final A1c decreased by
0.7–0.8% units. The A1c decreased from
9.5 ± 1.7% (at baseline) to about 2% final A1c
in insulin-naı¨ve subjects. In the present study,
Table 3 Multivariable logistic regression models for factors associated with more responsive glycemic control on basal
insulin
Model 1 Model 2
OR (95% CI) p value OR (95% CI) p value
Age 1.04 (1.01–1.07) 0.01 1.04 (1.01–1.07) 0.02
Sex 0.51 (0.25–1.05) 0.07 0.73 (0.35–1.49) 0.38
BMI 0.99 (0.90–1.09) 0.82 0.98 (0.89–1.08) 0.71
Duration of diabetes 0.95 (0.90–1.00) 0.03 0.93 (0.89–0.99) 0.01
Total cholesterol 1.01 (0.70–1.45) 0.96 1.13 (0.78–1.64) 0.51
A1C 0.76 (0.63–0.92) \0.01 0.72 (0.59–0.88) \0.01
PPG 0.70 (0.62–0.80) \0.01
PPG-FPG (D glucose) 0.84 (0.74–0.95) \0.01
A1c glycated hemoglobin, BMI Body mass index, FPG fasting plasma glucose, ND not determined OR odd ratio, PPG
postprandial glucose
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in group II (A1c C7.5%), baseline A1c was
9.8 ± 1.8%, which is similar to the existing
research. This study is not for the degree of A1c
reduction, but for an analysis about what
conditions could target A1c less than 7.5%.
These are the reasons why the results are
different from the previous study. A number of
studies have shown that a higher baseline A1c
group has a large delta A1c changes, which is
similar to the findings in this study. However,
in the case of basal insulin treatment, people
with higher baseline A1c might have difficulty
to reach the target A1c less than 7.5% in spite of
greater decrease during 6 months.
The appropriate choice of an insulin regime
for initiation of therapy has always been
difficult. There were several simple objective
ways to select the basal insulin; High FPG levels
should prompt a basal insulin prescription,
postprandial glucose excursion (mg%) \40,
low prandial:fasting index \0.4, high ratio of
fasting plasma glucose/A1c C20 (mg%/%). The
diurnal glucose profile is useful in selecting the
form of insulin therapy in type 2 diabetes [15].
These previous findings are consistent with the
result of this study that once-daily detemir
therapy was more effective in patients who
had well-controlled glycemic status (lower A1c,
smaller prandial glucose excursion, lower
postprandial glucose). Reduction in HbA1c
levels was found across both older and
younger age groups without an increased risk
of hypoglycemia or weight gain [8]. Biphasic
and prandial insulin regimens may lead to
better glycemic control than basal insulin
therapy [16]. This could make inferences that
the patients who had preserved beta cell
function in shorter duration of diabetes, and
not taking sulfonylurea would be able to have
better response to the basal insulin regimen.
Most Korean physicians preferred morning
injections of insulin detemir over evening
injections. Once-daily injections in the
morning showed significant A1c-lowering
effects but increased overall hypoglycemic
episodes. These desirable glycemic effects and
undesirable hypoglycemic episodes might be
due to increased insulin doses in the morning
injections. Although the doses of insulin in the
morning injections were significantly higher,
this did not affect the increase in the body
weight. Previous studies showed consistent with
the findings in our study which was once daily
insulin detemir is not associated with weight
gain [17]. A majority of the patients were
injected with detemir in the morning in real
clinical practice. While an evening injection is
recommended by the available guidelines
[18–20], results have shown that morning and
evening administration of detemir were
associated with reductions in A1c [21]. The
morning administration group had a larger
insulin dose, but they had fewer hypoglycemic
events and only 500 g more weight gain
compared to the evening administration group
[21]. The Korean Diabetes Association does not
clearly indicate the injection time of BI
treatment. The primary physicians preferred
morning injection of BI analog might be more
comfortable for the patients and effective in
glycemic control. This might be an explanation
for morning preference in BI therapy.
Observational studies include a wide range of
study designs, a defining feature of which is that
any intervention studied is determined by
clinical practice and not by the protocol. Data
from large, prospective observational studies
provide information about the safety and
efficacy of medicines in daily clinical use.
However, observational trials have inherent
limitations in terms of their susceptibility to
bias, restricting their ability to define causality.
However, their strengths include that they
reflect daily clinical practice more closely than
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randomized controlled trials, both in terms of
the heterogeneous patient populations that are
included, and the medical interventions that
they receive [22]. Similarly, our study has
several disadvantages of an observational
study. First, we did not adjust for a number of
confounding variables faced in actual clinical
practice. Second, the comparison between
patients injecting detemir in the evening with
those injecting in the morning is weakened by a
small number of patients in the former group.
The A1chieve study, by nature of its design, has
a number of limitations that must be considered
when interpreting the data [2]. Third, in terms
of the subjects’ baseline characteristics, we
could not figure out detailed withdrawal
reasons, previous drug use including statin,
and there were no statistical results on the
difference between the subjects who withdrew
from the study and the subjects who completed
the study.
CONCLUSION
This analysis was a sub-analysis of the A1chieve
study in Korea which demonstrated the efficacy
and safety of once-daily BI therapy
administered in the morning. Once-daily BI
therapy might be preferable in patients with
T2D with non-SU-treated diabetes of a shorter
duration with smaller postprandial glucose
excursion.
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